Pfizer to spend $11.6B on migraine treatment maker Biohaven
Pfizer is starting to put its covid-19 cash influx to use by spending $11.6 billion to venture deeper into a new treatment area.
Pfizer is starting to put its covid-19 cash influx to use by spending $11.6 billion to venture deeper into a new treatment area.